Bluenote
Website: https://www.bluenotehealth.com/
Bluenote helps scientists, researchers, and medical writers accelerate critical workflows by 50–75%—so you can spend less time on paperwork and more time advancing life-saving therapies.
Advanced computing is a strategic imperative for pharmaceutical innovation. The industry is at a point where traditional computational methods are no longer sufficient to solve the increasingly complex problems in R&D and operations. Embracing technologies like quantum computing and HPC is critical for maintaining a competitive edge and driving breakthroughs.
A hybrid approach is essential for a complete solution. No single technology is the silver bullet. The most effective solutions come from using the right tools—be it classical, quantum, or quantum-inspired—and combining them into a single, powerful workflow to maximize efficiency and impact. This approach allows companies to apply the best technology to a wide range of problems across the business, not just in drug discovery.
Strategic partnerships are key to capability building. For a large enterprise like J&J, the path to adopting these advanced technologies is best navigated through collaboration. Working with a specialist like Strangeworks bridges the knowledge gap, provides access to powerful platforms, and helps overcome organizational hurdles. The ultimate goal of this collaborations like these is to be able to empower J&J's internal teams to become self-sufficient pioneers of innovation.
Steve Gibson
Chief Commercial Officer
Strangeworks
Steve has held a range of C-Suite positions in technology companies ranging from financial technology services, to data science consulting. Currently he serves as Chief Commercial Officer at Strangeworks; an advanced compute platform as a service (PaaS) company based in Austin, Texas. Prior to Strangeworks, Steve helped build several startups from the ground up, the most successful being Honest Dollar which was the first startup acquired by Goldman Sachs in their 147 year history. Prior to Honest Dollar, Steve worked for a number of large multinational corporations in the European aerospace sector delivering platforms for military, civil and space applications. Steve holds a Bachelor’s degree in Aerospace Systems Engineering from the University of Coventry in the UK.
Selene Sass
Technology Product Manager
Johnson and Johnson
Selene is a technology product manager at Johnson & Johnson with nearly five years supporting the Advanced Computing and Analytics team. Her primary focus is to empower R&D scientists with emerging and innovative technologies in the advanced computing space, including the integration of quantum computing within J&J. Currently, she supports groups working in AI/ML and is exploring how quantum computing techniques can further enhance these capabilities.
Strangeworks
Website: https://strangeworks.com/
Strangeworks is on a mission to turn computational complexity into real world solutions. With the largest catalog of quantum and quantum-inspired computing resources on an innovative cloud platform backed by computational experts, we make the transformative potential of quantum computing accessible to all. Our AI powered workflows make it easier for enterprises to solve today’s toughest challenges, accelerate breakthroughs, and future-proof their operations. Partnering with customers worldwide, Strangeworks delivers immediate ROI while shaping a smarter, quantum-enabled future.
Helix AI
Website: https://helixai.com/
HelixAI is a specialist scientific technology company focused on accelerating research and development for biopharmaceutical organizations. Its platform, JarvisAI, enables scientific teams to design and execute in silico R&D workflows that support a wide range of operations from early-stage drug discovery to scale-up and bioproduction. By integrating scientific data from public, private and client domains along with computational models and AI-driven orchestration, JarvisAI helps researchers explore hypotheses more efficiently and prioritize the most promising drug candidates for further development. This approach supports better, faster decision-making combined with optimization of scientific and wet-lab resources.
- Learn how AI analyzes patent and R&D data to identify chemical trends, aiding in compound optimization.
- Discover how integrating diverse data sources streamlines the optimization of drug candidates, enhancing decision-making.
Sam Winters
Account Director
Patsnap
Sam is the lead representative for the healthcare and life sciences team at Patsnap. One of the organization’s longest serving employees, Sam works closely with our leading customers and the Patsnap product development team to ensure that our customers’ needs our met and that Patsnap continues to rapidly expand the technical frontier within the evolving drug discovery space.
Patsnap
Website: https://www.patsnap.com/
Patsnap enables IP and R&D teams to make faster, more informed decisions through advanced AI-powered intelligence. As the global leader in innovation intelligence since 2007, Patsnap provides comprehensive insights that enhance productivity and reduce inefficiencies. Patsnap's domain-specific large language model, trained on extensive proprietary innovation data, integrates with its suite of AI agents to deliver actionable intelligence that increases IP productivity by 75% and reduces R&D waste by 25%. The platform supports seamless collaboration across the complete innovation lifecycle, from patent analysis to competitive intelligence. More than 15,000 companies worldwide, including NASA, PayPal, Sanofi, Dow Chemical, and Wilson Sonsini, trust Patsnap to advance their innovation capabilities through AI.
Christina V. McDonough
Principal
Fish & Richardson P.C.
Christina McDonough helps clients with patent prosecution, portfolio management, reexamination, counseling, and due diligence for clients ranging from small start-ups to large companies and academic institutions. She co-leads the firm’s standard essential patent (SEP) practice.
Christina has particular expertise in the areas of artificial intelligence, digital therapeutics, bioinformatics and medical systems (e.g., telehealth, medical registries, readmission reductions, modeling and predictive analysis of biological data, genetic codes, and immunotherapy response), computational fluid dynamics (e.g., simulation of acoustic and fluid flow properties), complex data processing (e.g., big data and complex events), and financial algorithms (e.g., predictive modeling and forecasting of real-time security trades).
Crystal Culhane Ph.D.
Principal
Fish & Richardson P.C.
Crystal Culhane, Ph.D., applies her extensive academic background in organic chemistry to help life sciences organization protect their products and innovations through U.S. and foreign patent prosecution, client counseling, due diligence, patentability and freedom to operate opinions, patent opinions, and post-grant proceedings.
Known as a responsive communicator with a strong depth of knowledge, Crystal works with clients ranging from universities to start-ups and growing companies to multinational organizations to prepare intellectual property strategies that suit their business goals.
In recent years, Crystal has worked with a number of pharmaceutical clients in high-impact patent prosecution. Her clients include a large pharmaceutical company for which she has helped develop and manage a portfolio of several hundred patent families and another which in 2021 received its first-ever FDA approval for a new drug that treats a rare liver disease.
Crystal earned her doctorate in chemistry at Johns Hopkins University, where her research focused on the design, synthesis, and evaluation of novel optical and radioactive small molecule prostate cancer imaging agents. She has significant experience in various scientific disciplines, including synthetic organic chemistry, radiochemistry, biology, radiobiology, and small animal imaging.
Fish & Richardson
Website: https://www.fr.com/industries/life-sciences/
Fish & Richardson has represented pioneering life science innovators from our earliest days. We work closely with life sciences companies to help them achieve their strategic IP goals through acquisition, partnering, licensing, financing, and enforcement. We do this by bringing a unique holistic approach to our clients’ IP matters, fostered by the collaboration between our patent prosecution, litigation, and regulatory practices. We have helped our clients build valuable patent portfolios worth billions of dollars, score big victories at the Patent Trial and Appeal Board (PTAB), and win bet-the-company cases in court. When life sciences clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP.
Jeremy Hill
VP, Payer Solutions
Optum
Join us for a demo showcasing the power of Google Cloud TPU by walking through the complete lifecycle of a model, from post-training to inference at massive scale.
We’ll show you how to post-train a model using new RL capabilities in MaxText and Tunix, then take that same model and serve it on TPU seamlessly with the new JAX backend in vLLM.
Learn about how to rightsize a workload for TPU for both training and inference, optimizing for performance-per-dollar from beginning to end.
Brittany Rockwell
Product Manager
Google Cloud
Brittany Rockwell is a Product Manager for AI Inference at Google Cloud, where she leads the development of the TPU backend in vLLM, the most popular OSS library for language model inference. She currently lives in Seattle, WA.
Kyle Meggs
Product Manager
Google Cloud
Kyle Meggs is a Product Manager for JAX on Google Cloud. He enjoys helping customers train LLMs with MaxText and diffusion models with MaxDiffusion on the latest TPUs and GPUs.
Google Cloud provides leading infrastructure, platform capabilities, and industry solutions. We deliver enterprise-grade cloud solutions that leverage Google’s cutting-edge technology to help companies operate more efficiently and adapt to changing needs, giving customers a foundation for the future. Customers in more than 150 countries use Google Cloud as their trusted partner to solve their most critical business problems.
The transition to direct liquid cooling introduces challenges from unavoidable leaks, risking catastrophic hardware failure, costly downtime, and data loss– until now. actnano is AI's Missing Layer: the last line of defense for these mission critical assets. Our next-generation coating is the first truly proactive protection strategy for data infrastructure. Witness our live demonstration where an actnano-coated graphics card operates flawlessly while subjected to a simulated leak of conductive coolant. This technology engineers catastrophic failures into simple maintenance events, making hardware truly liquid-proof. See firsthand how to de-risk investments and unlock a new era of resilience, sustainability, and uptime.
Ken Aduddell
Senior Director
actnano
Ken Aduddell is a thought leader in data infrastructure with over 20 years of experience in the electronics industry. A trusted partner to executives at hyperscalers, his work has focused on the core challenges of data center resilience, including power and coolant systems. An established contributor to the Open Compute Project on the data center resilience chain, Ken offers deep insight into de-risking the inevitable transition to direct liquid cooling and protecting the mission-critical assets that power the AI era. Previously at Rockwell Automation, Ken now leads actnano's initiative to protect critical hardware with this breakthrough coating technology.
Actnano
Website: https://actnano.com/
actnano: AI’s Missing Layer
actnano is a global leader in surface protection for electronics. Over a decade ago, we redefined the industry by solving the biggest challenges with traditional coatings for the world's most demanding applications, including automotive. Today, our foundational battle-hardened, PFAS-free technology protects critical electronics in over 20 million vehicles produced annually. Now, we are bringing this same innovative DNA to address the greatest reliability risk in the AI data center: liquid cooling leaks. Our new line of purpose-designed coatings provides the essential protection to ensure the uptime, data integrity, and performance of the mission-critical AI systems that will define tomorrow.
We’re not just protecting electronics - we’re protecting the future of AI. Learn more at www.actnano.com